Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like Enzymotec Reports First Quarter 2017 Unaudited Financial Results May 16, 2017 New York's Akari Puts CEO on Administrative Leave May 11, 2017 Roche Gets in on Bay Area Allakos' $100M Funding Round December 12, 2017
